Cell-based lung cancer model could unlock targeted treatments
Scientists at the Cancer Research Manchester Institute have created a new model of Lung Squamous Cell Carcinoma (LUSC) to study the development, activity, and vulnerabilities of the disease.
In the UK, around 80 to 85% of lung cancers are non-small cell lung cancer, of which squamous cell carcinoma is one of the main types.
Despite this, LUSC remains poorly understood and treatment options are limited. Just one in five (21%) of lung cancer patients in England survive their disease for five years or more.
Researchers say the new cell-based model could help develop more effective treatments. It also has the potential to improve early detection of LUSC as it accurately reproduces the early stages of the disease.
Cancer Research UK Manchester Institute Fellow, Dr Carlos Lopez-Garcia, said: “With this new strategy to model lung squamous cell carcinoma, we are in a much better position to understand how this disease progresses. Developments like these accelerate research on new therapies and improve existing ones, powering us through clinical advancements for years to come.”
An alternative to animal testing
The study was funded by Cancer Research UK and the NC3Rs, a UK-based scientific organisation that aims to replace, reduce and refine the use of animals in research, along with support from the Rosetrees Trust.
The new LUSC model will both offer an alternative to animal testing and allow faster, cheaper, and larger experiments to be conducted.
To build it, scientists took healthy lung cells from three donors and used techniques including CRISPR gene editing to make the cells cancerous. This step-by-step process enabled the team to unravel the mutations needed to turn healthy cells into cancer cells, which was replicable across all three donors.
Professor Caroline Dive, Interim Director of the Cancer Research UK Manchester Insitute and Director of the Cancer Research UK National Biomarker Centre, said: “These new models are helping us gain a better understanding of how lung cancer develops and offer a very exciting opportunity to find new therapeutic vulnerabilities in this hard-to-treat cancer. It is also exciting to see an approach like this which helps bridge the gap between research in the lab and in animal models, which ultimately brings benefit to patients.”
Diana Spencer, Senior Digital Content Editor, DDW
